Salvage effect of E5564, Toll‐like receptor 4 antagonist on d‐galactosamine and lipopolysaccharide‐induced acute liver failure in rats
Authors:
- 28 April 2010
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 25 (5) , 1009-1012
Abstract
Background and Aims: The transmembrane protein Toll‐like receptor 4 (TLR4), which exists mainly in macrophages such as Kupffer cells of the liver, plays an important role in recognizing and mediating macrophage activation and pro‐inflammatory cytokine release. Activation of the pro‐inflammatory cytokine cascade, including tumor necrosis factor‐alpha (TNF‐α), has a pivotal role in the progression of severe liver injury. D‐galactosamine (GalN) and lipopolysaccharide (LPS)‐induced liver injury in rats is an experimental model of fulminant hepatic failure, where TNF‐α plays a central role in the progression of liver injury. E5564, a synthetic analogue of the lipid A component of endotoxin, inhibits endotoxin‐stimulated inflammation and is under study for patients with sepsis. In the present study, we sought to explore the salvage effect of TLR4 antagonist E5564 on GalN+LPS‐induced acute liver failure (ALF) in rats.Methods: ALF was induced in male Wistar rats by the intraperitoneal injection of GalN (500 mg/kg) and LPS (50 µg/kg). Immediately after GalN+LPS injection, rats were treated with intravenous injection of E5564 (3 mg/kg). The cumulative survival rates of GalN+LPS‐induced ALF rats were compared between those with and without E5564 treatment.Results: The intravenous injection of E5564 reduced the elevation of serum total bilirubin, aspartate aminotransferase, alanine aminotransferase and TNF‐α levels in rats at 3 h after GalN+LPS injection, and improved the survival rate of GalN+LPS‐induced ALF rats at 24 h (8% vs 43%).Conclusions: TLR4 antagonist E5564 reduced GalN+LPS‐induced acute liver injury in rats and improved the overall survival rate of GalN+LPS‐induced ALF rats. It may contribute to the treatment of ALF through blocking endotoxin‐induced TNF‐α overproduction of macrophages.Keywords
This publication has 23 references indexed in Scilit:
- Therapeutic approach to regulate innate immune response by Toll‐like receptor 4 antagonist E5564 in rats with D‐galactosamine‐induced acute severe liver injuryJournal of Gastroenterology and Hepatology, 2009
- Expression of Toll‐like receptor 4 in various organs in rats with d‐galactosamine‐induced acute hepatic failureJournal of Gastroenterology and Hepatology, 2008
- Toll-Like Receptor Signaling in the LiverGastroenterology, 2006
- Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2 in miceHepatology, 2004
- Inhibition of Endotoxin Response by E5564, a Novel Toll-Like Receptor 4-Directed Endotoxin AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Recognition of pathogen-associated molecular patterns by TLR familyImmunology Letters, 2003
- IRAK-M Is a Negative Regulator of Toll-like Receptor SignalingCell, 2002
- Human models of innate immunity: local and systemic inflammatory responsesInnate Immunity, 2001
- The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-αHepatology, 1992
- Bacterial Endotoxins (Part 1 of 2)International Archives of Allergy and Immunology, 1975